Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.25 -2.99% -0.10
BCRX closed down 2.99 percent on Tuesday, July 23, 2019, on 87 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Aug 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BCRX trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -2.99%
Lower Bollinger Band Walk Weakness -2.99%
BB Squeeze Ended Range Expansion -2.99%
Below Lower BB Weakness -2.99%
Lower Bollinger Band Touch Weakness -2.99%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Chemistry Biotechnology Diseases Chemical Compounds Enzymes Gout Seasonal Influenza Acetamides
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.95
52 Week Low 2.8
Average Volume 2,682,110
200-Day Moving Average 7.1313
50-Day Moving Average 4.0062
20-Day Moving Average 3.57
10-Day Moving Average 3.488
Average True Range 0.1906
ADX 18.11
+DI 16.4304
-DI 28.6539
Chandelier Exit (Long, 3 ATRs ) 3.4082
Chandelier Exit (Short, 3 ATRs ) 3.8118
Upper Bollinger Band 3.8264
Lower Bollinger Band 3.3136
Percent B (%b) -0.12
BandWidth 14.364146
MACD Line -0.1939
MACD Signal Line -0.2117
MACD Histogram 0.0178
Fundamentals Value
Market Cap 261.39 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -5.24
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.49
Resistance 3 (R3) 3.51 3.46 3.45
Resistance 2 (R2) 3.46 3.40 3.45 3.44
Resistance 1 (R1) 3.35 3.36 3.33 3.33 3.42
Pivot Point 3.30 3.30 3.28 3.29 3.30
Support 1 (S1) 3.19 3.24 3.17 3.17 3.08
Support 2 (S2) 3.14 3.20 3.13 3.06
Support 3 (S3) 3.03 3.14 3.05
Support 4 (S4) 3.01